{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T07:55:36Z","timestamp":1791705336955,"version":"4.3.4"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The third Sustainable Development Goal (SDG), to ensure healthy lives and promote well-being for all at all ages, has particular relevance and implementation challenges amongst people living with rare diseases such as cystic fibrosis (CF). Although the treatment and projected outcome of CF has significantly improved with the advent of CF transmembrane conductance regulator protein modulator (CFTRm) therapy, there remains significant global inequality with regards to access to these life-saving and life-altering drugs. Elexacaftor, tezacaftor, and ivacaftor (ETI) triple combination therapy, first licensed in the United States in 2019, has rapidly become the standard of care for children aged 6 years and older in most high-income countries for individuals with CFTR variants responsive to ETI. Negotiated agreements for access to ETI are currently in place in North America,Europe, Israel ,Australia and New Zealand. However, less priority has been given to negotiate agreements for access to CFTRm in low-middle income countries(LMIC) with significant CF populations such as Central and South America, India, the Middle East, and Southern Africa. These countries and individuals living with CF are therefore effectively being left behind, in direct conflict with the stated principle of the 2030 SDGs. In this review, we highlight the current global inequity in access to CFTRm drugs and its impact on widening disparities between high-income countries and LMIC in CF outcomes and survival. We further discuss the reasons for this inequity and explore the ethical- and human rights-based principles and dilemmas that clinicians, families, governments, and healthcare funders must consider when prioritizing fair and affordable access to expensive CFTRm drugs. Lastly, we propose possible solutions to overcoming the barriers to accessing affordable CFTRm drugs in LMIC and illustrate with examples how access to drug therapies for other conditions have been successfully negotiated in LMIC through innovative partnerships between governments and pharmaceutical industries.<\/jats:p>","DOI":"10.3389\/fphar.2023.1163391","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T05:39:01Z","timestamp":1679895541000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":68,"title":["Real-world disparities and ethical considerations with access to CFTR modulator drugs: Mind the gap!"],"prefix":"10.3389","volume":"14","author":[{"given":"M.","family":"Zampoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. M","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"B1","unstructured":"Association for accessible medicines2022"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.prrv.2020.05.002","article-title":"CFTR modulator therapies - effect on life expectancy in people with cystic fibrosis","volume":"42","author":"Balfour-Lynn","year":"2022","journal-title":"Paediatr. Respir. Rev."},{"key":"B3","volume-title":"Principles of biomedical ethics","author":"Beauchamp","year":"2001"},{"key":"B4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: A global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s41030-021-00170-9","article-title":"CFTR modulator therapy and its impact on lung transplantation in cystic fibrosis","volume":"7","author":"Benden","year":"2021","journal-title":"Pulm. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3390\/jcm11041021","article-title":"Elexacaftor\/Tezacaftor\/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study","volume":"11","author":"Carnovale","year":"2022","journal-title":"J. Clin. Med."},{"key":"B7","unstructured":"Cystic Fibrosis Foundation annual data report2022"},{"key":"B8","unstructured":"Inside the UK's drug buyers' clubs-BBC News\n            CohenD.\n          2019"},{"key":"B9","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1126\/science.1084564","article-title":"The human Genome Project: Lessons from large-scale biology","volume":"300","author":"Collins","year":"2003","journal-title":"Science"},{"key":"B10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.prrv.2020.07.004","article-title":"Cystic fibrosis in low-middle income countries (LMIC): A view from four different regions of the world","volume":"38","author":"da Silva Filho","year":"2021","journal-title":"Paediatr. Respir. Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/hec.924","article-title":"QALY maximisation and people's preferences: A methodological review of the literature","volume":"14","author":"Dolan","year":"2005","journal-title":"Health Econ."},{"key":"B12","first-page":"65","article-title":"Wto: US and Argentina settle dispute over patents and data protection","volume":"7","author":"Elliott","year":"2002","journal-title":"Can. HIV AIDS Policy Law Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A global reference for human genetic variation","volume":"526","author":"Genomes Project","year":"2015","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1136\/jme.2003.007138","article-title":"Ethical issues in funding orphan drug research and development","volume":"31","author":"Gericke","year":"2005","journal-title":"J. Med. Ethics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ccm.2022.06.009","article-title":"Update on clinical outcomes of highly effective modulator therapy","volume":"43","author":"Gifford","year":"2022","journal-title":"Clin. Chest Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"","journal-title":"J. Cyst. Fibros."},{"key":"B17","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.jcf.2022.04.007","article-title":"Current prices versus minimum costs of production for CFTR modulators","volume":"21","author":"Guo","year":"","journal-title":"J. Cyst. Fibros."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/1471-2458-12-198","article-title":"Socioeconomic inequality in domains of health: Results from the world health surveys","volume":"12","author":"Hosseinpoor","year":"2012","journal-title":"BMC Public Health"},{"key":"B20","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/qjmed\/hci128","article-title":"Drugs for exceptionally rare diseases: Do they deserve special status for funding?","volume":"98","author":"Hughes","year":"2005","journal-title":"QJM"},{"key":"B21","doi-asserted-by":"publisher","first-page":"059563","DOI":"10.1377\/forefront.20170412.059563","article-title":"Value frameworks for rare diseases: Should they be different?","volume":"2017","author":"Jena","year":"2017","journal-title":"Health Aff. Forefr."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.2147\/RMHP.S260641","article-title":"Ethical questions linked to rare diseases and orphan drugs - a systematic review","volume":"13","author":"Kacetl","year":"2020","journal-title":"Risk Manag. Healthc. Policy"},{"key":"B23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jcf.2005.10.002","article-title":"Carrier frequency of F508del mutation of cystic fibrosis in Indian population","volume":"5","author":"Kapoor","year":"2006","journal-title":"J. Cyst. Fibros."},{"key":"B24","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1136\/thoraxjnl-2020-216265","article-title":"Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials","volume":"77","author":"Keogh","year":"2022","journal-title":"Thorax"},{"key":"B25","doi-asserted-by":"publisher","first-page":"692","DOI":"10.2146\/ajhp130348","article-title":"Health disparities: Exploring the ethics of orphan drugs","volume":"71","author":"Kinney","year":"2014","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B26","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1136\/jme.25.3.224","article-title":"Equitable rationing of highly specialised health care services for children: A perspective from South Africa","volume":"25","author":"Landman","year":"1999","journal-title":"J. Med. Ethics"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: The changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"26318","DOI":"10.1002\/ppul.26318","article-title":"Clinical change 2 years from start of elexacaftor-tezacaftor-ivacaftor in severe cystic fibrosis","volume":"2023","author":"McCoy","year":"2023","journal-title":"Pediatr. Pulmonol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"26335","DOI":"10.1002\/ppul.26335","article-title":"How many billions is enough? Prioritizing profits over patients with cystic fibrosis","volume":"2023","author":"McGarry","year":"2023","journal-title":"Pediatr. Pulmonol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.prrv.2021.12.001","article-title":"Left behind: The potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis","volume":"42","author":"McGarry","year":"2022","journal-title":"Paediatr. Respir. Rev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/ppul.25285","article-title":"Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype","volume":"56","author":"McGarry","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"B32","unstructured":"M\u00e9decins Sans Fronti\u00e8res technical briefing document2020"},{"key":"B33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1513\/AnnalsATS.202010-1274ED","article-title":"Social inequities and cystic fibrosis outcomes: We can do better","volume":"18","author":"Oates","year":"2021","journal-title":"Ann. Am. Thorac. Soc."},{"key":"B34","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.jval.2018.01.008","article-title":"Evaluating and valuing drugs for rare conditions: No easy answers","volume":"21","author":"Ollendorf","year":"2018","journal-title":"Value Health"},{"key":"B35","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1378\/chest.09-0345","article-title":"Impact of socioeconomic status, race, and ethnicity on quality of life in patients with cystic fibrosis in the United States","volume":"137","author":"Quittner","year":"2010","journal-title":"Chest"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3390\/cells11111769","article-title":"CFTR modulators in people with cystic fibrosis: Real-world evidence in France","volume":"11","author":"Regard","year":"2022","journal-title":"Cells"},{"key":"B37","unstructured":"Miracle cystic fibrosis drug kept out of reach in developing countries\n            RobbinsS. N. R.\n          2023"},{"key":"B38","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1164\/rccm.201503-0578OC","article-title":"Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data","volume":"192","author":"Sawicki","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3390\/genes11060589","article-title":"The changing epidemiology of cystic fibrosis: Incidence, survival and impact of the CFTR gene discovery","volume":"11","author":"Scotet","year":"2020","journal-title":"Genes (Basel)."},{"key":"B40","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(22)01013-3","article-title":"Accelerating pooled licensing of medicines to enhance global production and equitable access","volume":"400","author":"Shadlen","year":"2022","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12881-020-01153-4","article-title":"NGS-based expanded carrier screening for genetic disorders in North Indian population reveals unexpected results - a pilot study","volume":"21","author":"Singh","year":"2020","journal-title":"BMC Med. Genet."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1111\/resp.12656","article-title":"Epidemiology and genetics of cystic fibrosis in Asia: In preparation for the next-generation treatments","volume":"20","author":"Singh","year":"2015","journal-title":"Respirology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jcf.2020.07.017","article-title":"Projecting the impact of delayed access to elexacaftor\/tezacaftor\/ivacaftor for people with Cystic Fibrosis","volume":"20","author":"Stanojevic","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1513\/AnnalsATS.201606-481FR","article-title":"Cystic fibrosis in the african diaspora","volume":"14","author":"Stewart","year":"2017","journal-title":"Ann. Am. Thorac. Soc."},{"key":"B45","volume-title":"Committee for development policy report - records of the economic and social council","year":"2018"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/j.gim.2022.06.009","article-title":"CFTR genotype analysis of Asians in international registries highlights disparities in the diagnosis and treatment of Asian patients with cystic fibrosis","volume":"24","author":"Vaidyanathan","year":"2022","journal-title":"Genet. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"B48","unstructured":"Vertex Save us2023"},{"key":"B49","unstructured":"Social determinants of health: Health equity2023"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e215","DOI":"10.1016\/j.jcf.2022.03.006","article-title":"Global access to affordable CFTR modulator drugs: Time for action!","volume":"21","author":"Zampoli","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B51","doi-asserted-by":"publisher","first-page":"00856","DOI":"10.1183\/23120541.00856-2020","article-title":"Cystic fibrosis in South Africa: Spectrum of disease and determinants of outcome","volume":"7","author":"Zampoli","year":"2021","journal-title":"ERJ open Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1163391\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T05:39:07Z","timestamp":1679895547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1163391\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":51,"alternative-id":["10.3389\/fphar.2023.1163391"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1163391","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,27]]},"article-number":"1163391"}}